Core Viewpoint - The article discusses the upcoming Global Medical Robotics Conference 2025, focusing on the evolution of surgical robots and the complexities of the medical robotics industry, emphasizing the need for innovation and collaboration among various stakeholders [2][6]. Group 1: Conference Details - The conference will take place on September 5-6, 2025, at the Beijing Zhongguancun National Independent Innovation Demonstration Zone Exhibition and Trading Center [3]. - The agenda includes an opening ceremony, a visit to a robot leasing hospital, and a high-level dinner for executives [3]. Group 2: Key Themes and Topics - The conference will cover topics such as technological systems and intelligent evolution, commercialization and hospital system implementation, global strategies and pathways for expansion, and the integration of medical engineering and technology transfer [4][5][7]. - The event will also feature the release of the "Global Surgical Robot Industry Report 2025" and an annual award ceremony recognizing achievements in the medical robotics field [6]. Group 3: Industry Trends and Challenges - The article highlights the core architectural trends of next-generation surgical robots, including AI integration, intraoperative navigation, and the challenges of integrating robotic systems with hospital infrastructures [7][10]. - It discusses the importance of building a global leading R&D system and clinical validation loops, as well as the commercialization pathways for surgical robots across different markets [7][10]. Group 4: Supply Chain and Ecosystem - The article emphasizes the need for a complete medical robotics industry chain and the importance of collaboration between domestic and international supply chains [10][8]. - It also addresses the challenges of training systems, maintenance frameworks, and remote support in creating an intelligent ecosystem for surgical robots [10][8]. Group 5: Participation and Awards - The conference invites various entities, including enterprises, hospitals, and research institutions, to participate in award nominations, with a maximum of three awards per entity [16]. - The evaluation mechanism includes expert reviews, industry nominations, and public voting for certain awards, providing significant exposure for winning entities [16].

Group 1 - The core viewpoint of the article highlights the opportunities for the health consumption sector in China due to the aging population and supportive government policies, as outlined in the "Action Plan for Promoting Healthy Consumption" released by 12 departments including the Ministry of Commerce and the National Health Commission [1] - The discussion at the "European Forum" in Paris emphasized the rapid development of China's medical innovation sector and the unique opportunities for Sino-European cooperation in healthcare, as stated by former French Health Minister Olivier Véran [1][3] - Véran noted that cooperation between China and Europe could lead to both regions becoming long-term partners and global leaders in healthcare, with China needing access to European markets and Europe seeking to deepen connections with Chinese innovation resources [1][3] Group 2 - Olivier Dessajan, CEO of High Life China and President of the French Health Industry Alliance, expressed the importance of collaboration with China, stating that not engaging with China would be a mistake [3] - The establishment of high-end medical service nursing homes in cities like Guangzhou, Hangzhou, and Shenzhen by High Life China reflects the adaptation to local regulations while incorporating French operational mechanisms [3] - The CEO of Pro Pharma, Zhu Fangmeng, emphasized the significance of Sino-European cooperation in innovation and manufacturing, noting that nearly one-third of their overseas market is in Europe [3] Group 3 - The discussion highlighted the advanced technologies available in France and Europe, such as confocal endoscopy and radiofrequency ablation devices, while China leads in AI-assisted treatments and clinical trial results [4] - Véran pointed out the important reforms China has made to facilitate the entry of biopharmaceutical companies into the European market, particularly in modernizing drug regulations and accelerating clinical trials [4] - The strategy for AI application in healthcare should balance caution and innovation to promote harmonious economic relations and public interest between China and Europe, according to Véran [4]

文章来源：骨未来 转载要求：可以直接转载，请在文首注明来源 大会由骨未来、智汇骨、思宇MedTech 主办 ， 中关村联新生物医药产业联盟、北京中关村科学城创新 发展有限公司、启迪之星、中关村创业大街科技服务有限公司、中关村科学城CGT产业孵化中心协办 ， 吸引了来自全国各地的600余位临床专家、科研学者、企业代表和投资人，围绕骨科科技创新、医工交 叉、集采政策、手术机器人等热点话题展开深入交流与讨论。 # 高规格开幕，政府、医院、媒体三方联动 大会开幕式由思宇MedTech创始人、骨未来主编、中关村联新生物医药产业联盟秘书长赵清主持。 开幕式上， 北京市 海淀区副区长 林航 表示， 海淀将以更开放的机制、更精准的服务支持骨科创新，推 动更多像骨科机器人、生物材料这样的好产品从"临床需求"出发、从"海淀出发"，走向全国。 2025年4月24日， 首届全球骨科大会（Global Orthopedics Conference 2025）在北京市中关村自主 创新示范区展示中心隆重举行。 北京市医药健康科技发展中心主任 刘慧 指出， 北京正以"政策牵引+平台建设+三医协同"为抓手，持续强化临床需求导向的科技创新体 系 ...

Core Viewpoint - The domestic surgical robot industry is experiencing accelerated commercialization, with strong certainty for import substitution as multiple domestic surgical robots have been approved for market entry, gradually breaking the monopoly of the Da Vinci surgical robot from Intuitive Surgical [2]. Group 1: Market Dynamics - The domestic market for surgical robots, particularly laparoscopic surgical robots, is currently dominated by the Da Vinci system, which holds a market share of 46.9% in 2024, down 16.3 percentage points year-on-year [2]. - The total number of laparoscopic surgical robots expected to be awarded in 2024 is approximately 98 units, representing a 71.9% increase compared to about 57 units in 2023, driven by the recovery of tendering processes and industry equipment updates [3]. Group 2: Policy and Regulatory Environment - The "14th Five-Year" plan for large medical equipment configuration is nearing completion, with the total planned number of laparoscopic surgical robots set at 559 units, indicating a potential increase in tendering and installation progress as more domestic surgical robots gain approval [3]. Group 3: Competitive Landscape - The competition in the laparoscopic robot market is moderate, with a strong certainty of market share increase for domestic companies. The orthopedic robot sector is currently facing intensified competition [4]. - Companies with strong research and development capabilities, backed by large medical groups and possessing commercial experience, are expected to perform well in the market, while innovative domestic companies with competitive pricing and product performance are likely to gradually increase their market share [4].